Loading...
•
Jun 30, 2021
Pacific Biosciences Q2 2021 Earnings Report
Pacific Biosciences' Q2 2021 earnings demonstrated strong growth and strategic progress.
Key Takeaways
Pacific Biosciences reported revenue of $30.5 million for Q2 2021, a 107% increase year-over-year. The company's performance was driven by increased instrument revenue and consumables revenue. The company is increasing full year revenue guidance to 112-118 million.
Revenue was $30.5 million, up 107% year-over-year.
Instrument revenue was $16.4 million, up 208% year-over-year.
Consumables revenue was $11.4 million, up 49% year-over-year.
Service and other revenue was $2.7 million, up 30% year-over-year.
Revenue by Segment
Forward Guidance
Pacific Biosciences is increasing its full year 2021 revenue guidance to $112 million to $118 million.
Positive Outlook
- Increasing full year 2021 revenue guidance to $112 million to $118 million.
- Continued strong demand for Sequel II/IIe systems.
- Growing consumables revenue base.
- Expanding market opportunities for long-read sequencing.
- Strategic collaborations driving technology adoption.
Challenges Ahead
- Uncertainties related to the COVID-19 pandemic.
- Potential supply chain disruptions.
- Increased competition in the sequencing market.
- Fluctuations in foreign currency exchange rates.
- Dependence on key collaborations and partnerships.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...